<!DOCTYPE html SYSTEM "about:legacy-compat">
<html lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>.05 Cost Review Study. | Library of Maryland Regulations</title>
    <link rel="shortcut icon" href="/us/md/exec/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="full-html" content="/us/md/exec/comar/14.01/index.full.html" data-document="href"/>
    <meta itemprop="toc-json" content="/us/md/exec/comar/14.01/index.json" data-document="href"/>
    <meta itemprop="parent-doc-url" content="/us/md/exec/comar" data-document="href"/>
    <meta itemprop="order" content="|14|01|04|.05|"/>
    <meta itemprop="doc-type" content="section" data-document=""/>
    <meta itemprop="ref-doc" content="Code of Maryland Regulations" data-document=""/>
    <meta itemprop="ref-path" content="14|01|04|.05" data-document=""/>
    <!--OpenGraph-->
    <meta property="og:url" content="http://regs.maryland.gov//us/md/exec/comar/14.01.04.05"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content=".05 Cost Review Study. | Library of Maryland Regulations"/>
    <meta property="og:image" content="http://regs.maryland.gov//us/md/exec/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#0078EF"/>
    <meta name="apple-mobile-web-app-title" content="Library of Maryland Regulations"/>
    <meta name="theme-color" content="#0078EF"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/md/exec/_document/v2/images/favicons/safari-pinned-tab.svg" color="#0078EF"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/md/exec/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/md/exec/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/md/exec/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/md/exec/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/public-sans/public-sans.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/merriweather/merriweather.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/roboto-mono/roboto-mono.css" type="text/css" rel="stylesheet" data-document=""/>
    <!--Document CSS-->
    <link href="/us/md/exec/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print" data-document=""/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js" data-document=""> </script>
    <!--Links to resources that need to be prefetched-->
    <link rel="prefetch" href="/us/md/exec/comar/14.01/index.full.html" as="fetch"/>
    <link rel="prefetch" href="/index.json" as="fetch"/>
    <link rel="prefetch" href="/us/md/exec/comar/14.01/index.json" as="fetch"/>
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__maryland-dsd">
      <header id="section__header" class="ns__document__maryland-dsd">
        <div id="section__header__inner" class="ns__document__maryland-dsd">
          <div id="area__logo" class="ns__document__maryland-dsd">
            <a href="/" class="logo" aria-label="Logo - Return to library home page">
              <img src="/us/md/exec/_document/v2/images/logo/logo.png" srcset="/us/md/exec/_document/v2/images/logo/logo.png 1x, /us/md/exec/_document/v2/images/logo/logo@2x.png 2x, /us/md/exec/_document/v2/images/logo/logo@3x.png 3x" alt="Library of Maryland Regulations logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__maryland-dsd">
            <div class="h__library-logotype"><span class="line1">Library of</span> <span class="line2">Maryland Regulations</span></div>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__maryland-dsd">
        <div id="section__content__inner" class="ns__document__maryland-dsd">
          <section id="area__breadcrumbs" class="ns__document__maryland-dsd" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="Library of Maryland Regulations">Library of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations" data-search-heading="" data-search-default="true" class="li__book-open">
                  <a href="/us/md/exec/comar" title="Code of Maryland Regulations">Code of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|14" data-search-heading="">
                  <a href="/us/md/exec/comar/14" title="Title 14 INDEPENDENT AGENCIES">Title 14 INDEPENDENT AGENCIES</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|14|01" data-search-heading="">
                  <a href="/us/md/exec/comar/14.01" title="Subtitle 01 PRESCRIPTION DRUG AFFORDABILITY BOARD">Subtitle 01 PRESCRIPTION DRUG AFFORDABILITY BOARD</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|14|01|04" data-search-heading="">
                  <a href="/us/md/exec/comar/14.01.04" title="Chapter 04 Cost Review Study Process">Chapter 04 Cost Review Study Process</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|14|01|04|.05" data-search-heading="">
                  <span title=".05 Cost Review Study.">.05 Cost Review Study.</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__maryland-dsd">
            <div class="h__document-title">Code of Maryland Regulations</div>
            <article class="content" role="document" data-ref-path="14|01|04|.05">
              <div class="tuf-authenticate">
                <h1 class="h__toc" id="/us/md/exec/comar/14.01.04.05">.05 Cost Review Study.</h1>
                <p class="text-indent-1 "><span class="level-num" id="A">A.</span> The Board may determine:</p>
                <p class="text-indent-2 "><span class="level-num" id="A(1)">(1)</span> Whether use of the prescription drug product has led or will lead to:</p>
                <p class="text-indent-3 "><span class="level-num" id="A(1)(a)">(a)</span> Affordability challenges to the State health care system; or</p>
                <p class="text-indent-3 "><span class="level-num" id="A(1)(b)">(b)</span> High out-of-pocket costs for patients;</p>
                <p class="text-indent-2 "><span class="level-num" id="A(2)">(2)</span> Whether the use that has led to affordability challenges or high out-of-pocket costs is consistent with:</p>
                <p class="text-indent-3 "><span class="level-num" id="A(2)(a)">(a)</span> The labeling approved by the FDA; or</p>
                <p class="text-indent-3 "><span class="level-num" id="A(2)(b)">(b)</span> Standard medical practice; and</p>
                <p class="text-indent-2 "><span class="level-num" id="A(3)">(3)</span> The circumstances under which the prescription drug product has or will lead to an affordability challenge to the State health care system or high out-of-pocket costs to patients under <a class="internal-link " href="/us/md/exec/comar/14.01.04.05#A(1)" title="">§A(1) of this regulation</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="B">B.</span> Analyses and Data Compilation.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(1)">(1)</span> To the extent practicable, Board staff may assemble the data and analyses specified by Health-General Article §21-2C-09(b), Annotated Code of Maryland, and this regulation for consideration by the Board, including the data elements and information provided to the Board under Regulation .03A and B of this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="B(2)">(2)</span> These data and analyses may be:</p>
                <p class="text-indent-3 "><span class="level-num" id="B(2)(a)">(a)</span> Derived from published peer-reviewed literature;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(2)(b)">(b)</span> Derived from published public sources such as the FDA Orange Book, the FDA Purple Book, and other sources;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(2)(c)">(c)</span> Reported by or derived from manufacturers, health insurance plans, HMOs, MCOs, PBMs, and wholesale distributors;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(2)(d)">(d)</span> Produced by Board staff through analysis;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(2)(e)">(e)</span> Derived from external analyses and modeling studies;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(2)(f)">(f)</span> Derived from the MCDB, any claims set of the MCDB, and any other databases containing relevant information;</p>
                <p class="text-indent-3 "><span class="level-num" id="B(2)(g)">(g)</span> Derived from reports generated by U.S. governmental entities, State governmental entities, foreign governmental and quasi-governmental agencies, and U.S. and foreign non-profit organizations; or</p>
                <p class="text-indent-3 "><span class="level-num" id="B(2)(h)">(h)</span> Derived from quantitative and qualitative data collected by Board staff.</p>
                <p class="text-indent-1 "><span class="level-num" id="C">C.</span> Factors Considered in Cost Review Study.</p>
                <p class="text-indent-2 "><span class="level-num" id="C(1)">(1)</span> To the extent practicable, the Board may consider the following data, information, and analyses in conducting a cost review study:</p>
                <p class="text-indent-3 "><span class="level-num" id="C(1)(a)">(a)</span> Drug Pricing for Drug Product Under Review:</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(a)(i)">(i)</span> The WAC, AWP, NADAC, SAAC, ASP, and FSS; and</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(a)(ii)">(ii)</span> Information estimating manufacturer net price and net sales amounts of the prescription drug product under review;</p>
                <p class="text-indent-3 "><span class="level-num" id="C(1)(b)">(b)</span> Price Concessions, Discounts, and Rebates:</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(b)(i)">(i)</span> The average price concession, discount, and rebate provided by the manufacturer or expected to be provided to each payor class in the State for the drug under review, expressed as a number and as a percent of the WAC; and</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(b)(ii)">(ii)</span> The average price concession, discount, and rebate the manufacturer provided or is expected to provide for the prescription drug product under review to each PBM operating in the State, expressed as a number and as a percent of the WAC;</p>
                <p class="text-indent-3 "><span class="level-num" id="C(1)(c)">(c)</span> Therapeutic Alternatives:</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(c)(i)">(i)</span> The average price concession, discount, or rebate the manufacturer provides or is expected to provide to health plans in the State for therapeutic alternatives;</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(c)(ii)">(ii)</span> The WAC, AWP, NADAC, SAAC, ASP, and FSS at which each therapeutic alternative has been sold in the State; and</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(c)(iii)">(iii)</span> The utilization, costs, and out-of-pocket costs for therapeutic alternatives;</p>
                <p class="text-indent-3 "><span class="level-num" id="C(1)(d)">(d)</span> Patient Access:</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(d)(i)">(i)</span> The costs to health plans based on patient access consistent with FDA-labeled indications or standard medical practice;</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(d)(ii)">(ii)</span> The estimated impact on patient access resulting from the cost of the prescription drug product relative to insurance benefit design; and</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(d)(iii)">(iii)</span> The current or expected dollar value of drug-specific patient access programs that are supported by the manufacturer for the drug product under review and the policies surrounding and implementing such programs;</p>
                <p class="text-indent-3 "><span class="level-num" id="C(1)(e)">(e)</span> Cost and Comparative Effectiveness Analyses:</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(e)(i)">(i)</span> The incremental costs associated with a prescription drug product, including financial impacts to health, medical, or social services as can be quantified and compared to baseline effects of existing therapeutic alternatives; and</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(e)(ii)">(ii)</span> Information derived from health economics and outcomes research that may address the effectiveness of the prescription drug product in treating the conditions for which it is prescribed or in improving a patient’s health, quality of life, or overall health outcomes, and the effectiveness of the prescription drug product compared with therapeutic alternatives or no treatment.</p>
                <p class="text-indent-3 "><span class="level-num" id="C(1)(f)">(f)</span> Cost Sharing:</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(f)(i)">(i)</span> The average patient copay and other cost-sharing data for the prescription drug in the State; and</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(f)(ii)">(ii)</span> The average cost share; and</p>
                <p class="text-indent-3 "><span class="level-num" id="C(1)(g)">(g)</span> Additional Board Factors:</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(i)">(i)</span> Clinical information, including FDA indications and doses and information concerning standard medical practice;</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(ii)">(ii)</span> The disease burden of the condition that is treated by the prescription drug product;</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(iii)">(iii)</span> In the case of generic prescription drug products, the number of pharmaceutical manufacturers that produce the prescription drug product;</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(iv)">(iv)</span> The total gross spending in the State for the prescription drug product under review, the total number of patients in the State using the prescription drug product, and the percentage of overall total prescription drug product spending that the product’s spending represents;</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(v)">(v)</span> The change in total gross spending and utilization for a prescription drug product in the State between the two most recent available calendar years and the percent change in total gross spending for a prescription drug product in the State between the two most recent available calendar years;</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(vi)">(vi)</span> The mean, median, and 90th percentile out-of-pocket costs per patient compared to State incomes;</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(vii)">(vii)</span> An assessment of the impact of the prescription drug product’s cost to access by priority populations and the impact on equity;</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(viii)">(viii)</span> Information supplied by the manufacturer, if any, explaining the relationship between the pricing of the prescription drug product and (a) the cost of development and (b) the therapeutic benefit of the prescription drug product, or information that is otherwise pertinent to the manufacturer’s pricing decision;</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(ix)">(ix)</span> Analysis of the prescription drug product’s approval process;</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(x)">(x)</span> Analysis of the prescription drug product’s shortage status;</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(xi)">(xi)</span> Analysis of the market context of the prescription drug product including the prescription drug product’s lifecycle management, patent management, regulatory exclusivities, and product hopping;</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(xii)">(xii)</span> The utilization and pricing of therapeutically equivalent drug products;</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(xiii)">(xiii)</span> Analysis of the impact of state and federal regulatory and compliance issues related to the prescription drug product;</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(xiv)">(xiv)</span> Input from state and local governmental entities and the entities’ contractors such as health plans and plan administrators;</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(xv)">(xv)</span> Impact of the utilization and spending for the prescription drug product on public budgets and comparison of the spending on the prescription drug product to relevant benchmarks;</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(xvi)">(xvi)</span> Analyses and research including literature review by Board staff in response to information submitted by an entity under <a class="internal-link " href="/us/md/exec/comar/14.01.04.04" title=".04 Request for Information for Cost Review.">Regulation .04 of this chapter</a>, or through any public comment or public input procedure</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(xvii)">(xvii)</span> Input from the public; and</p>
                <p class="text-indent-4 "><span class="level-num" id="C(1)(g)(xviii)">(xviii)</span> Information and analyses submitted by an entity under <a class="internal-link " href="/us/md/exec/comar/14.01.04.04" title=".04 Request for Information for Cost Review.">Regulation .04 of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="C(2)">(2)</span> The public may provide written comments concerning the prescription drug product:</p>
                <p class="text-indent-3 "><span class="level-num" id="C(2)(a)">(a)</span> Within 60 days of the date the drug’s selection for cost review study is posted on the Board’s website; and</p>
                <p class="text-indent-3 "><span class="level-num" id="C(2)(b)">(b)</span> In accordance with the procedures in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#B(3)" title="">COMAR 14.01.01.05B(3)</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="D">D.</span> At an open meeting, the Board may:</p>
                <p class="text-indent-2 "><span class="level-num" id="D(1)">(1)</span> Hear oral public comments concerning the prescription drug product in accordance with the procedures in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05#A" title="">COMAR 14.01.01.05A</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="D(2)">(2)</span> To the extent permitted by Health-General Article, §§21-2C-03 and 21-2C-10, Annotated Code of Maryland, consider written comments submitted in accordance with the procedures in <a class="internal-link no-wrap" href="/us/md/exec/comar/14.01.01.05" title=".05 Public Comment Procedures.">COMAR 14.01.01.05</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="D(3)">(3)</span> To the extent practicable, and in compliance with Health-General Article, §21-2C-03(e)(1)(iv), Annotated Code of Maryland, consider the data and analyses specified by <a class="internal-link " href="/us/md/exec/comar/14.01.04.05#C" title="">§C of this regulation</a>, including the data elements and information provided to the Board under <a class="internal-link " href="/us/md/exec/comar/14.01.04.03" title=".03 Selecting Drugs for Cost Review.">Regulation .03 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="D(4)">(4)</span> Close the session to discuss confidential, trade-secret, and proprietary information; and</p>
                <p class="text-indent-2 "><span class="level-num" id="D(5)">(5)</span> Preliminarily determine whether:</p>
                <p class="text-indent-3 "><span class="level-num" id="D(5)(a)">(a)</span> Use of the prescription drug product, identified by NDC, has led or will lead to:</p>
                <p class="text-indent-4 "><span class="level-num" id="D(5)(a)(i)">(i)</span> Affordability challenges to the State health care system; or</p>
                <p class="text-indent-4 "><span class="level-num" id="D(5)(a)(ii)">(ii)</span> High out-of-pocket costs for patients; and</p>
                <p class="text-indent-3 "><span class="level-num" id="D(5)(b)">(b)</span> Whether the use that has led to affordability challenges or high out-of-pocket costs is consistent with:</p>
                <p class="text-indent-4 "><span class="level-num" id="D(5)(b)(i)">(i)</span> The labeling approved by the FDA; or</p>
                <p class="text-indent-4 "><span class="level-num" id="D(5)(b)(ii)">(ii)</span> Standard medical practice.</p>
                <p class="text-indent-1 "><span class="level-num" id="E">E.</span> If the Board is unable to determine whether a prescription drug product will produce or has produced challenges to the affordability of the prescription drug product for the State health care system, the Board may consider:</p>
                <p class="text-indent-2 "><span class="level-num" id="E(1)">(1)</span> The additional factors identified in Health-General Article, §21-2C-09(b)(3)(i)—(iv), Annotated Code of Maryland; and</p>
                <p class="text-indent-2 "><span class="level-num" id="E(2)">(2)</span> The following additional factors:</p>
                <p class="text-indent-3 "><span class="level-num" id="E(2)(a)">(a)</span> Federal support for the research and development of the prescription drug product; and</p>
                <p class="text-indent-3 "><span class="level-num" id="E(2)(b)">(b)</span> Pricing data from other countries for the prescription drug product.</p>
                <p class="text-indent-1 "><span class="level-num" id="F">F.</span> Preliminary Determination.</p>
                <p class="text-indent-2 "><span class="level-num" id="F(1)">(1)</span> In accordance with <a class="internal-link " href="/us/md/exec/comar/14.01.04.05#C" title="">§C of this regulation</a>, the Board may make a preliminary determination of whether use of the prescription drug product has led or will lead to affordability challenges for the State health care system or high out-of-pocket costs for patients.</p>
                <p class="text-indent-2 "><span class="level-num" id="F(2)">(2)</span> A preliminary determination is non-final and subject to revision and modification.</p>
                <p class="text-indent-2 "><span class="level-num" id="F(3)">(3)</span> Preliminary Determination of Affordability Challenge.</p>
                <p class="text-indent-3 "><span class="level-num" id="F(3)(a)">(a)</span> Board staff shall prepare a draft of the preliminary determination cost review report that summarizes the information considered by the Board in conducting the cost review study, the Board’s deliberations, the circumstances or indicia reflecting the affordability challenge, and the Board’s preliminary determination.</p>
                <p class="text-indent-3 "><span class="level-num" id="F(3)(b)">(b)</span> The public may comment on the draft of the preliminary determination cost review report.</p>
                <p class="text-indent-1 "><span class="level-num" id="G">G.</span> Final Determination Concerning Affordability Challenge and Final Cost Review Study Report.</p>
                <p class="text-indent-2 "><span class="level-num" id="G(1)">(1)</span> The Board may vote to finalize the preliminary determination and approve the draft cost review report as final.</p>
                <p class="text-indent-2 "><span class="level-num" id="G(2)">(2)</span> The Board’s determination of whether a prescription drug has or will lead to an affordability challenge is not final until the final cost review report is adopted by the Board.</p>
                <p class="text-indent-2 "><span class="level-num" id="G(3)">(3)</span> The Board shall create and adopt a final report of the cost review study that, to the extent permitted by Health-General Article, §§21-2C-03 and 21-2C-10, Annotated Code of Maryland, summarizes the information considered by the Board in conducting the cost review study, the Board’s deliberations, and the Board’s determination.</p>
              </div>
            </article>
          </main>
          <nav id="area__navigation_mini" class="ns__document__maryland-dsd" aria-label="Previous and next article links">
            <section>
              <a href="/us/md/exec/comar/14.01.04.04" aria-label=".04 Request for Information for Cost Review.">
                <div class="h__ui">Previous</div>
                <span>.04 Request for Information for Cost Review.</span>
              </a>
            </section>
            <section>
              <a href="/us/md/exec/comar/14.01.05" aria-label="Chapter 05 Consumer Regulations">
                <div class="h__ui">Next</div>
                <span>Chapter 05 Consumer Regulations</span>
              </a>
            </section>
          </nav>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__maryland-dsd">
        <div id="section__footer__inner" class="ns__document__maryland-dsd">
          <div id="area__footer__content" class="ns__document__maryland-dsd">
<p>This version of the laws and codes on this website is licensed under the <a href="https://creativecommons.org/licenses/by-nc-sa/4.0/">CC BY-NC-SA 4.0</a> license with copyright held by the State of Maryland.</p><p>This version of the laws and codes on this website will be dedicated to the public domain under the <a href="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0</a> license 180 days after publication.</p>
<p>
      Please do not scrape. Instead, bulk download the CC BY-NC-SA-4.0 <a href="https://github.com/maryland-dsd/law-html">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml">XML</a> or CC0 <a href="https://github.com/maryland-dsd/law-html-cc0">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml-cc0">XML</a>.
    </p><p>Powered by the non-profit <a href="https://www.openlawlib.org/">Open Law Library</a>.</p></div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
